Education, Research & Positions
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial Summary The KEYNOTE-426 trial investigated pembrolizumab plus axitinib versus sunitinib for advanced clear Read More
